Sec Form 4/A Filing - COUCHMAN JONATHAN @ ENZON PHARMACEUTICALS, INC. - 2020-03-13

FORM 4/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person COUCHMAN JONATHAN 2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS, INC. [ ENZN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 600 FIFTH AVENUE, 2ND FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 03/13/2020 (Street) NEW YORK, NY10020 4. If Amendment, Date Original Filed (MM/DD/YY) 03/27/2020 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, $0.01 par value ( 1 ) 03/13/2020 P 19,709 A $ 0.135 1,594,232 I By Xstelos Corp. ( 2 ) Common Stock, $0.01 par value ( 1 ) 03/23/2020 P 2,678 A $ 0.14 2,928 I By Myrexis, Inc. ( 4 ) Common Stock, $0.01 par value ( 1 ) 03/25/2020 P 469,551 A $ 0.14 472,479 I By Myrexis, Inc. ( 4 ) Common Stock, $0.01 par value ( 1 ) 03/26/2020 P 160,785 A $ 0.14 633,264 I By Myrexis, Inc. ( 4 ) Common Stock, $0.01 par value ( 1 ) 4,717,666 D Common Stock, $0.01 par value ( 1 ) 400,000 I By Couchman Family Fund ( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other COUCHMAN JONATHAN 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY10020 X Couchman Family Fund 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY10020 See Footnote 1 Xstelos Corp. 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY10020 See Footnote 1 Myrexis, Inc. 600 FIFTH AVENUE, 2ND FLOOR NEW YORK, NY10020 See Footnote 1 Signatures /s/ Jonathan Couchman 03/31/2020 Signature of Reporting Person Date Couchman Family Fund; By: /s/ Jonathan Couchman, Trustee 03/31/2020 Signature of Reporting Person Date Xstelos Corp.; By: /s/ Jonathan Couchman, Chief Executive Officer 03/31/2020 Signature of Reporting Person Date Myrexis, Inc.; By: /s/ Jonathan Couchman, Chief Executive Officer 03/31/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis" and, together with Mr. Couchman, the Foundation and Xstelos, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose. ( 2 )Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein. ( 3 )Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares. ( 4 )Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

Remarks: This amended Form 4 is filed on behalf of the Reporting Persons because as of the original filing date, Myrexis did not have the necessary SEC filing codes. Myrexis has since obtained the necessary filing codes and the Reporting Persons are filing this amendment accordingly.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.